Company profile: SQI Diagnostics
1.1 - Company Overview
Company description
- Provider of medical systems and diagnostics leveraging proprietary multiplexing, miniaturization, and automation; offerings include RALI-Dx IL-6 Severity Triage for COVID-19, rapid mobile PCR testing, Sofia SARS Antigen FIA, Sofia2 Flu+SARS Antigen FIA, QuickVue At-Home OTC COVID-19 test, and the TORdx LUNG test under development to assess donor lung health.
Products and services
- RALI-Dx IL-6 Severity Triage Test: Proprietary diagnostic measuring IL-6 concentrations in human plasma to assist triage by identifying severe inflammatory responses in COVID-19 patients
- Rapid Mobile PCR Testing for COVID-19: Portable, real-time PCR assay delivering approximately 90-minute results for on-site COVID-19 detection across diverse settings
- TORdx LUNG Test: Under-development assay architected to assess donor lung health for transplantation by detecting inflammation at the molecular level
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SQI Diagnostics
XVIVO
HQ: Sweden
Website
- Description: Provider of organ perfusion, preservation, and assessment solutions for transplantation, including XPS for ex vivo lung perfusion and assessment; Liver Assist for hypothermic, normothermic, and sub-normothermic liver preservation; Kidney Assist Transport for hypothermic pulsatile perfusion of donor kidneys up to 24 hours; PERFADEX Plus for static cold storage of lungs; STEEN Solution for lung assessment; and XVIVO Academy training.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XVIVO company profile →
Oxford Immunotec
HQ: United Kingdom
Website
- Description: Provider of medical diagnostic tests based on patented T cell measurement technology, including T-SPOT.TB, an interferon gamma release assay for diagnosing latent TB infection and TB disease; T-SPOT.CMV for detecting cytomegalovirus infections; and T-SPOT.PRT for assessing immune responses to various pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Immunotec company profile →
OSE Immunotherapeutics
HQ: France
Website
- Description: Provider of immunotherapies in immuno-oncology, auto-immune diseases, and transplantation, with a pipeline including Tedopi (Phase 3 cancer vaccine for NSCLC resistant to checkpoint inhibitors), OSE-279 (anti-PD1), BI 765063/OSE-172 (SIRPα), OSE-127 (IL-7R; ulcerative colitis), FR104 (CD28; renal transplantation), and OSE-230 (ChemR23; chronic inflammatory diseases).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OSE Immunotherapeutics company profile →
Organ Transport Systems
HQ: United States
Website
- Description: Provider of portable, hypothermic, oxygenated preservation and transport technology for human organs, offering the LifeCradle HR durable perfusion unit and a complementing single-use organ chamber and fluid circuit kit.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Organ Transport Systems company profile →
TransMedics
HQ: United States
Website
- Description: Provider of organ preservation technology and clinical service solutions for transplantation, offering OCS Heart, OCS Lung, and OCS Liver systems that keep donor organs functional for viability assessment and transport; the National OCS Program with technology, clinical services, and training; and the OCS Lung Solution for flushing, storage, and transportation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TransMedics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SQI Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SQI Diagnostics
2.2 - Growth funds investing in similar companies to SQI Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SQI Diagnostics
4.2 - Public trading comparable groups for SQI Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →